Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuadrise Regulatory News (QED)

Share Price Information for Quadrise (QED)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.01 (0.45%)
Bid:
2.01
Ask:
2.19
Spread: 0.18 (8.955%)
Market Cap: £44.34m
QED Live PriceLast checked at - London Stock Exchange

Intraday Quadrise Share Chart

Successful Sparkle Power Programme Testing

17 Sep 2025 07:00

RNS Number : 5968Z
Quadrise PLC
17 September 2025
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

17 September 2025

 

Quadrise plc

("Quadrise", "QED" or the "Company")

 

Successful completion of Sparkle Power testing programme

 

Quadrise plc (AIM: QED), the technology company focused on the decarbonisation of shipping and heavy industry through deployment of low emission fuels and biofuels, is pleased to announce the successful completion of proof-of-concept and emissions testing programmes for its MSAR® and bioMSAR™ fuels at the Sparkle Power SA ("Sparkle") plant in El Giral, Panama.

 

These trials mark the first successful application of MSAR® and bioMSAR™ on Everllence (formerly MAN Energy Solutions) 4-stroke engines, expanding the commercial potential of these fuels across additional engine types in energy-intensive sectors seeking cost-effective decarbonisation solutions.

 

Testing on MSAR® and bioMSAR™ fuels was conducted over a 24 hour period on an Everllence 18V32/40 8MW engine. A subsequent shorter run was completed on a Everllence 9L28/32 4MW engine. The trials were conducted by experts from Quadrise and Sparkle, and supported by independent specialists in external engine performance, emissions and fuel testing.

 

The key success criteria of the main trial were met as follows:

 

· Engine efficiency was improved, consistent with results on Wärtsilä diesel engines.

· NOx emissions were reduced by 25% with bioMSAR and 32% with MSAR®.

· Particulate matter emissions were reduced by 20% using both fuels.

 

The Sparkle trials validated the expected performance of MSAR® and bioMSAR™ for commercial deployment and confirmed the fuel injection system modifications required to achieve maximum load. The parties are now jointly planning the next steps towards confirming commercial supply arrangements for Sparkle and fuel permitting in Panama.

Jason Miles, Chief Technology Officer of Quadrise, commented:

"The successful trials with Sparkle represent a significant milestone for Quadrise, demonstrating the viability of MSAR® and bioMSAR™ on Everllence 4-stroke engines through a strong collaborative endeavour. With confirmed improvements in engine efficiency and emissions, we look forward to advancing discussions with Sparkle and a regional supply partner to establish a commercial supply facility serving the power and marine sectors across Central America."

Jose Castillo, General Manager of Sparkle, commented:

 

"We are delighted to have completed the Everllence engine test of MSAR® and bioMSAR™ at our power plant. The Quadrise test has confirmed the fuels are viable replacements for heavy fuel oil at our facility.

Sparkle Power is committed to becoming more fuel efficient and conserving the environment by reducing emissions in accordance with the government's policies for environmental conservation in Panama. The test has confirmed that MSAR® and bioMSAR™ fuels can achieve the necessary criteria for commercial implementation in the country."

 

For further information please contact:

 

Quadrise Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Technology Officer

 

 

Nominated Adviser

Cavendish Capital Markets Limited

 

 

+44 (0)20 7220 0500

Ben Jeynes

Katy Birkin

George Lawson

 

Joint Brokers

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs, Harry Davies-Ball (Corporate Advisory)

Fiona Conroy (Corporate Broking)

 

VSA Capital Limited

Andrew Raca (Corporate Finance)

Andrew Monk (Corporate Broking)

 

 

+44 (0)20 3005 5000

 

Public & Investor Relations

 

 

Tavistock Communications (Financial PR & IR)

Simon Hudson

Nick Elwes

Ruairi Millar

 

+44 (0) 20 7920 3150

 

 BLUE Communications Limited (Marine & Trade PR)

 Rhys Thomas

 Sam Deacon

 

 

 

+44 (0)7595 227750

+44 (0)7527 558846

 

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to lower energy costs, pollution and greenhouse gas emissions today for the global power generation, shipping, industrial and oil industries.

Learn more at: www.quadrise.com

 

Follow us on social media:

LinkedIn: @Quadrise Plc

X: @QuadrisePlc

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFFTASIRLIE
Date   Source Headline
1st Aug 20247:00 amRNSValkor Project Update
10th Jul 20247:00 amRNSMarine Project Update
26th Jun 20247:00 amRNSExtended agreement with BTG Bioliquids for bioMSAR
29th May 20247:00 amRNSRepresentation Agreement Addendum & Warrants Grant
28th May 20247:00 amRNSOCP Commercial Framework Agreement
2nd May 20247:00 amRNSQuadrise-Vertoro JDA to sea-trial bioMSAR Zero
29th Apr 20247:00 amRNSMarine Project Update
19th Apr 20247:00 amRNSValkor Project Update
12th Apr 20244:58 pmRNSResults of Open Offer
22nd Mar 20243:10 pmRNSExtension of Open Offer Closing Date
20th Mar 20241:01 pmRNSInvestor Presentation
19th Mar 20247:00 amRNSPlacing Results, Open Offer & Posting of Circular
18th Mar 20244:55 pmRNSProposed Placing, Subscription and Open Offer
18th Mar 20244:53 pmRNSInterim Results
15th Feb 20247:00 amRNSAgreement with Euthenia & BTG Bioliquids
6th Feb 20247:00 amRNSMarine Project Update
6th Dec 20237:00 amRNSUpdate re bioMSARâ„¢ and bioMSARâ„¢ Zero Development
27th Nov 20235:46 pmRNSResult of AGM
27th Nov 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSMorocco Project Update
9th Nov 20237:00 amRNSPublication of 2023 Sustainability Report
31st Oct 202312:45 pmRNSMorocco Project Update
27th Oct 20234:20 pmRNSPosting of Annual Report & Notice of AGM
24th Oct 20239:33 amRNSChange of Nominated Adviser
2nd Oct 20237:30 amRNSDirectorate Change
2nd Oct 20237:00 amRNSFinal Results and Notice of AGM
12th Sep 20237:00 amRNSMorocco Project Update
29th Aug 20237:00 amRNSValkor Project Update
24th Aug 202312:29 pmRNSValkor Update
18th Aug 20233:46 pmRNSMorocco Update
4th Aug 20237:00 amRNSIssue of Share Options and Director/PDMR Dealing
1st Aug 20234:15 pmRNSDirector/PDMR Shareholding
28th Jul 20234:25 pmRNSDirector/PDMR Shareholding
25th Jul 20233:34 pmRNSResults of Open Offer
7th Jul 202312:00 pmRNSInvestor Presentation
7th Jul 202310:38 amRNSPlacing Results, Open Offer & Posting of Circular
7th Jul 20237:00 amRNSProposed Placing and Open Offer
22nd Jun 20237:00 amRNSMorocco Update
12th Jun 20237:00 amRNSValkor Site License & Supply Agreement
8th Jun 20237:00 amRNSJoint Development Agreement with BTG Bioliquids
26th May 20237:00 amRNSVertoro Joint Development Agreement Update
22nd May 20237:00 amRNSMorocco Update
16th May 20234:29 pmRNSReplacement: Business Update
16th May 20237:00 amRNSBusiness Update
25th Apr 20237:00 amRNSAppointment of Joint Broker
29th Mar 20237:00 amRNSInterim Results
28th Mar 20237:00 amRNSChange of Company Name
22nd Oct 20155:26 pmRNSDelisting of Quintain ordinary shares
15th Oct 20154:30 pmRNSHolding(s) in Company
15th Oct 20154:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.